Edwards Lifesciences delivered a strong fourth quarter in 2025, with total sales growing 13.3% to $1.57 billion and adjusted EPS reaching $0.58. The company's TAVR and TMTT segments showed significant growth, contributing to an overall positive financial performance for the year.

Edwards Lifesciences reported $1.55 billion in revenue for Q3 2025, driven by robust growth in TAVR and TMTT sales. Gross and operating margins declined slightly YoY due to foreign exchange and investment-related spending. The company raised its full-year guidance.

The company delivered $1.53B in revenue, driven by solid TAVR and TMTT growth, with EPS of $0.57 and adjusted EPS of $0.67. Net income reached $333M, and guidance for full-year sales and EPS was raised.

The company delivered a strong start to 2025, with notable growth in TMTT and steady gains in TAVR. EPS and net income improved, bolstered by product adoption and operational efficiency.

Edwards Lifesciences reported strong Q4 FY24 results with revenue of $1.39 billion, a 9% increase year-over-year. EPS was $0.58, and adjusted EPS was $0.59. Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.04 billion, up 6%, while Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a substantial 88% growth to $105 million. Surgical Structural Heart sales were $244 million, increasing 6%. The company remains confident in its strategic growth areas, with continued expansion in structural heart therapies.

Edwards Lifesciences reported a 9% increase in sales from continuing operations, with constant currency sales growth of 10%. TAVR sales grew by 6%, while TMTT sales saw a significant increase of 73%. The company completed the sale of its Critical Care business and reiterated its full-year sales guidance.

Edwards Lifesciences reported a 7% sales growth in Q2, driven by a strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT) with 75% growth, which was offset by lower-than-expected growth in Transcatheter Aortic Valve Replacement (TAVR). The adjusted EPS was $0.70. The company expects full-year 2024 sales growth of 8 to 10%.

Edwards Lifesciences reported strong first-quarter results, with sales growing 10% to $1.6 billion and adjusted EPS of $0.66. The company has raised its full-year 2024 sales guidance due to this encouraging start of the year.

Edwards Lifesciences reported a strong Q4 2023, with sales up 14% to $1.53 billion and adjusted EPS of $0.64. The company is confident in its 2024 guidance, projecting 8 to 10 percent constant currency sales growth.

Edwards Lifesciences reported a 12% increase in sales to $1.48 billion in Q3 2023. The company's TAVR sales grew by 11%, and it received several regulatory approvals for its innovative therapies. The company reiterated its full-year 2023 financial guidance of 10 to 13 percent constant currency sales growth.

Edwards Lifesciences reported an 11% increase in sales to $1.53 billion in Q2 2023, with all product groups achieving double-digit constant currency sales growth. Adjusted EPS was $0.66. The company has increased its full-year outlook due to strong first-half performance and improved healthcare staffing.

Edwards Lifesciences reported a strong start to 2023, exceeding expectations with Q1 sales growing 9% to $1.46 billion and adjusted EPS of $0.62. The company raised its full-year sales guidance and expects a return to higher sales growth, driven by its patient-focused innovation strategy.

Edwards Lifesciences reported Q4 2022 results, with sales growing 1% to $1.35 billion and adjusted EPS increasing 25% to $0.64. The company highlighted progress on strategic milestones and reiterated its 2023 guidance.

Edwards Lifesciences reported Q3 sales of $1.32 billion, a 1% increase, or 7% on a constant currency basis. Adjusted EPS increased by 13% to $0.61. The company received U.S. FDA and CE Mark approval for PASCAL Precision and U.S. FDA approval for the SAPIEN 3 Ultra RESILIA valve.

Edwards Lifesciences reported flat sales of $1.37 billion in the second quarter of 2022, but underlying sales grew by 5%. EPS was $0.65, and adjusted EPS was $0.63. The company lowered its second-half underlying sales growth outlook to approximately 10% but expects strong double-digit adjusted EPS growth in the second half.

Edwards Lifesciences reported a 10% increase in sales to $1.34 billion in the first quarter, with underlying sales up 13%. The company reaffirmed its full-year financial guidance and saw growth across all regions and product lines.

Edwards Lifesciences reported a 12% increase in Q4 sales to $1.33 billion, with underlying growth of 13%. Adjusted EPS was $0.51. The company reaffirmed its full-year 2022 sales guidance and adjusted EPS expectations.

Edwards Lifesciences reported a 15% increase in sales to $1.3 billion for the third quarter of 2021. The company's TAVR sales grew by 15%, and it made progress on five pivotal trials in TMTT. The company maintained its full-year 2021 sales guidance range and EPS guidance.

Edwards Lifesciences reported a strong second quarter with sales up 49% to $1.4 billion and underlying sales growth of 44%. TAVR sales exceeded expectations, growing 52%. The company raised its full-year sales guidance to $5.2 to $5.4 billion and adjusted EPS guidance to the high end of the previous $2.07 to $2.27 range.

Edwards Lifesciences reported sales of $1.2 billion, an 8% increase over the prior year, with underlying sales growing by 5%. EPS reached $0.54, surpassing expectations. The company is confident in its 2021 outlook and raised its adjusted EPS guidance.

Edwards Lifesciences reported Q4 sales increased 1 percent to $1.2 billion, with underlying sales flat. The company's Q4 EPS was $0.49, and adjusted EPS grew 2 percent to $0.50. The company reiterated its 2021 guidance with sales growth expected in the mid-teens.

Edwards Lifesciences reported a 4% increase in sales to $1.1 billion for the third quarter of 2020. Diluted earnings per share were $0.52, and adjusted earnings per share grew 9% to $0.51. The company is raising the bottom end of full-year 2020 adjusted earnings per share guidance to $1.85 to $1.95.

Edwards Lifesciences reported a 15% decrease in sales to $925 million, with TAVR sales declining by 12%. EPS was negative $0.20, while adjusted EPS decreased 26% to $0.34. The company reiterated its 2020 sales guidance of $4.0 billion to $4.5 billion and increased its adjusted EPS guidance to $1.75 to $1.95.

Edwards Lifesciences reported a 14% increase in sales to $1.1 billion for the first quarter of 2020. Diluted EPS was $1.47, and adjusted EPS grew 14% to $1.51. The company's sales were significantly impacted by COVID-19 in the last few weeks of the quarter, leading to a substantial reduction in 2020 sales and EPS guidance.

Edwards Lifesciences reported a strong fourth quarter with sales growth of 20% to $1.2 billion and adjusted EPS growth of 25% to $1.46. The company's full year sales and earnings significantly exceeded original guidance. 2020 guidance ranges increased: sales $4.6 billion to $5.0 billion; EPS $6.15 to $6.40